CLDX CELLDEX THERAPEUTICS INC NEW

Ownership history in Kynam Capital Management, LP  ·  18 quarters on record

This page tracks every 13F SEC filing in which Kynam Capital Management, LP reported a position in CELLDEX THERAPEUTICS INC NEW (CLDX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
14.4% (2023 Q3)
Avg. % of fund
9.58%
First filed
2021 Q4
Last filed
2025 Q4
Quarters held
18
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 REDUCED 5,943,180 -157,549 -2.6% 10.31% $161.4M $27.16
2025 Q3 UNCHANGED 6,100,729 0% 11.75% $157.8M $25.87
2025 Q2 REDUCED 6,100,729 -399,271 -6.1% 13.37% $124.1M $20.35
2025 Q1 ADDED 6,500,000 +1,435,793 +28.4% 9.91% $118.0M $18.15
2024 Q4 ADDED 5,064,207 +1,605,598 +46.4% 7.56% $128.0M $25.27
2024 Q3 ADDED 3,458,609 +69,642 +2.1% 9.01% $117.6M $33.99
2024 Q2 ADDED 3,388,967 +488,967 +16.9% 9.67% $125.4M $37.01
2024 Q1 REDUCED 2,900,000 -105,904 -3.5% 12.74% $121.7M $41.97
2023 Q4 REDUCED 3,005,904 -194,096 -6.1% 13.21% $119.2M $39.66
2023 Q3 ADDED 3,200,000 +600,000 +23.1% 14.40% $88.1M $27.52
8 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    CLDX price (monthly, adj. close)
← Back to Kynam Capital Management, LP Holdings